Daiichi Sankyo (4568.T) stock price, revenue, and financials

Daiichi Sankyo market cap is ¥5 t, and annual revenue was ¥981.79 b in FY 2019

¥5 T

4568.T Mkt cap, 14-Sept-2021

¥243.2 B

Daiichi Sankyo Revenue Q2, 2020
Daiichi Sankyo Gross profit (Q2, 2020)156.8 B
Daiichi Sankyo Gross profit margin (Q2, 2020), %64.5%
Daiichi Sankyo Net income (Q2, 2020)19.8 B
Daiichi Sankyo EBIT (Q2, 2020)24.3 B
Daiichi Sankyo Cash, 30-Sept-2020451.3 B
Daiichi Sankyo EV4.7 T
Get notified regarding key financial metrics and revenue changes at Daiichi SankyoLearn more
Banner background

Daiichi Sankyo Revenue

Daiichi Sankyo revenue was ¥981.79 b in FY, 2019 which is a 5.6% year over year increase from the previous period.

Embed Graph

Daiichi Sankyo Revenue Breakdown

Embed Graph

Daiichi Sankyo revenue breakdown by business segment: 92.8% from Prescription Drugs, 7.0% from Healthcare (OTC) Products and 0.2% from Other

Daiichi Sankyo revenue breakdown by geographic segment: 18.6% from North America, 9.8% from Europe, 61.9% from Japan and 9.7% from Other

Daiichi Sankyo Income Statement

Annual

JPYFY, 2017FY, 2018FY, 2019

Revenue

960.2b929.7b981.8b

Revenue growth, %

(3%)6%

Cost of goods sold

346.0b364.6b343.2b

Gross profit

614.2b565.1b638.6b

Gross profit Margin, %

64%61%65%

Sales and marketing expense

96.4b87.5b86.3b

R&D expense

236.0b203.7b197.5b

General and administrative expense

158.8b144.0b163.4b

Operating expense total

537.9b481.4b499.8b

Depreciation and amortization

46.7b46.2b52.6b

EBIT

76.3b83.7b138.8b

EBIT margin, %

8%9%14%

Interest expense

2.7b2.3b2.3b

Interest income

2.5b3.9b5.2b

Investment income

320.0m327.0m

Pre tax profit

81.0b85.8b141.2b

Income tax expense

21.2b(7.6b)12.2b

Net Income

59.8b93.4b129.0b

EPS

91.1143.9198.8

Daiichi Sankyo Balance Sheet

Annual

JPYFY, 2017FY, 2018FY, 2019

Cash

357.7b243.2b424.2b

Accounts Receivable

211.2b360.8b283.1b

Inventories

172.6b176.1b173.4b

Current Assets

1.2t1.4t1.4t

PP&E

217.9b229.1b247.1b

Goodwill

75.5b77.9b76.8b

Total Assets

1.9t2.1t2.1t

Accounts Payable

68.8b73.5b70.1b

Short-term debt

20.0b40.0b40.4b

Current Liabilities

353.1b384.5b351.1b

Long-term debt

260.6b220.6b183.8b

Non-Current Liabilities

411.6b453.8b448.3b

Total Debt

280.6b260.6b224.2b

Total Liabilities

764.7b838.3b799.3b

Common Stock

50.0b50.0b50.0b

Additional Paid-in Capital

94.6b94.6b94.6b

Retained Earnings

1.0t1.2t1.2t

Total Equity

1.1t1.2t1.3t

Debt to Equity Ratio

0.2 x0.2 x0.2 x

Debt to Assets Ratio

0.1 x0.1 x0.1 x

Financial Leverage

1.7 x1.7 x1.6 x

Daiichi Sankyo Cash Flow

Annual

JPYFY, 2017FY, 2018FY, 2019

Depreciation and Amortization

46.7b46.2b52.6b

Accounts Receivable

2.5b(187.8b)110.2b

Inventories

(19.4b)(4.0b)(7.4b)

Accounts Payable

238.0m60.4b(44.7b)

Cash From Operating Activities

108.4b92.0b196.6b

Purchases of PP&E

(23.4b)(36.1b)(31.9b)

Capital Expenditures

(14.6b)(30.5b)(20.6b)

Cash From Investing Activities

108.6b(142.5b)81.7b

Dividends Paid

(46.4b)(45.3b)(45.4b)

Cash From Financing Activities

(101.8b)(66.2b)(91.6b)

Net Change in Cash

115.2b(116.7b)186.6b

Interest Paid

2.0b1.8b2.5b

Income Taxes Paid

22.2b36.1b26.2b

Free Cash Flow

93.8b61.5b176.0b

Daiichi Sankyo Ratios

JPYFY, 2018

Revenue/Employee

66.5m

Debt/Equity

0.2 x

Debt/Assets

0.1 x

Financial Leverage

1.7 x

Daiichi Sankyo Operating Metrics

FY, 2018FY, 2019FY, 2020Aug, 2020Dec, 2020

Countries (Facilities)

24242424

Manufacturing Facilities

14141413

Patent Applications

415

Patents

316

Phase I Trials Products

16

Phase I Trials Products (Other)

2

Phase I/II Trials Products (Breast Cancer)

1

Phase I/II Trials Products (Gastric Cancer)

1

Phase II Trials Products

7

Phase II Trials Products (Breast Cancer)

1

Phase II Trials Products (Colorectal Cancer)

1

Phase II Trials Products (Gastric Cancer)

2

Phase II Trials Products (Lung Cancer)

2

Phase II Trials Products (Other)

1

Phase III Trials Products

7

Phase III Trials Products (Breast Cancer)

5

R&D Facilities

8141414

Trademark Applications

17

Trademarks

116

Daiichi Sankyo Human Capital

FY, 2020FY, 2019FY, 2018
Male, percent17.6%21.9%33%
Male (Senior Management), percent21.2%25.8%
Female (Management), percent6.9%7.5%10.7%
Female (Senior Management), percent6.3%7.5%
Female, percent9.9%11.5%16.9%
Male (Management), percent20.5%25.8%39.4%

Daiichi Sankyo Employee Rating

3.9527 votes
Culture & Values
3.6
Work/Life Balance
3.6
Senior Management
3.1
Salary & Benefits
3.8
Career Opportunities
3.3
Source